Premium
Fetal aortic valvuloplasty to prevent progression to hypoplastic left heart syndrome in utero
Author(s) -
Crystal Matthew A.,
Freud Lindsay R.
Publication year - 2019
Publication title -
birth defects research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.845
H-Index - 17
ISSN - 2472-1727
DOI - 10.1002/bdr2.1478
Subject(s) - hypoplastic left heart syndrome , in utero , medicine , aortic valvuloplasty , heart disease , fetus , intervention (counseling) , prenatal diagnosis , cardiology , pregnancy , intensive care medicine , surgery , aortic valve stenosis , aortic valve , psychiatry , biology , genetics
Advances in fetal echocardiography have allowed for the prenatal diagnosis of congenital heart disease and an understanding of its natural history in utero. This insight has led to the development of fetal cardiac intervention (FCI) for select defects to prevent significant morbidity or mortality postnatally. Fetal aortic valvuloplasty (FAV) may be performed to prevent progression to hypoplastic left heart syndrome, a severe form of congenital heart disease, in utero. The current review focuses on this type of FCI and discusses the history of FAV, the rationale for intervention, candidate selection, procedural technique, and outcomes to date. Finally, the importance of building a multidisciplinary team to perform FCI is addressed.